免疫检查点抑制剂治疗晚期非小细胞肺癌的预后标志物动态监测研究进展  

Advances in Dynamic Monitoring of Immune Checkpoint Inhibitors as the Prognostic Markers for Advanced Non⁃small Cell Lung Cancer

作　　者：代丽源 石远凯[2,3] 韩晓红 DAI Liyuan;SHI Yuankai;HAN Xiaohong(Department of Clinical Laboratory,National Cancer Center,National Clinical Research Center for Cancer,Beijing 100021,China;Department of Medical Oncology,National Cancer Center,National Clinical Research Center for Cancer,Beijing 100021,China;Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,National Cancer Center,National Clinical Research Center for Cancer,Beijing 100021,China;Clinical Pharmacology Research Center,NMPA Key Laboratory for Clinical Research and Evaluation of Drug,Beijing Key Laboratory of Clinical PK&PD Investigation for Innovative Drugs,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China;State Key Laboratory of Complex Severe and Rare Diseases,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)

机构地区：[1]国家癌症中心国家肿瘤临床医学研究中心中国医学科学院肿瘤医院检验科,北京100021 [2]国家癌症中心国家肿瘤临床医学研究中心中国医学科学院肿瘤医院内科,北京100021 [3]国家癌症中心国家肿瘤临床医学研究中心中国医学科学院肿瘤医院抗肿瘤分子靶向药物临床研究北京市重点实验室,北京100021 [4]中国医学科学院北京协和医院临床药理研究中心国家药品监督管理局药物临床研究与评价重点实验室创新药物临床药代药效研究北京市重点实验室,北京100730 [5]中国医学科学院北京协和医院疑难重症及罕见病国家重点实验室,北京100730

出　　处：《协和医学杂志》2022年第2期287-295,共9页Medical Journal of Peking Union Medical College Hospital

基　　金：国家“重大新药创制”科技重大专项(2019ZX09201⁃002,2017ZX09304015);2022首都卫生发展科研专项(2022⁃2z⁃4016)。

摘　　要：免疫检查点抑制剂在晚期非小细胞肺癌中的应用显著提高了患者的生存获益,但存在治疗反应率低等临床问题。免疫检查点抑制剂治疗是肿瘤⁃免疫系统交互对话、动态变化的过程,纵向监测生物标志物变化,有助于消除个体间的差异,提供肿瘤时空异质性信息。本文将从肿瘤细胞源性、免疫微环境源性及多指标联合三方面对免疫检查点抑制剂治疗晚期非小细胞肺癌预后标志物动态监测的相关研究进展进行综述。The use of immune checkpoint inhibitors(ICIs)in advanced non⁃small cell lung cancer(NSCLC)significantly improves survival,but it has clinical problems such as low response rate.Treatment of tumor with ICIs is a dynamic change that involves the process of tumor⁃immune system interaction.Vertical mo⁃nitoring of dynamic changes of biomarkers is helpful to eliminate individual differences and to provide information on spatiotemporal heterogeneity of tumors.This paper reviews the biomarkers of advanced NSCLC,cov⁃ering the aspects of treatment with ICIs from tumor cell origin,immune microenvironmental source and joint in⁃dicators.

关 键 词：免疫治疗 非小细胞肺癌 动态监测 预后标志物 免疫检查点抑制剂 

分 类 号：R734.2[医药卫生—肿瘤] R730.3[医药卫生—临床医学]